SBIR Phase I: Bioresorbable Polyurethane Scaffold Materials for Regenerative Applications in Advanced Wound Healing

Information

  • NSF Award
  • 0944877
Owner
  • Award Id
    0944877
  • Award Effective Date
    1/1/2010 - 14 years ago
  • Award Expiration Date
    12/31/2010 - 13 years ago
  • Award Amount
    $ 200,000.00
  • Award Instrument
    Standard Grant

SBIR Phase I: Bioresorbable Polyurethane Scaffold Materials for Regenerative Applications in Advanced Wound Healing

This Small Business Innovation Research (SBIR) Phase I project aims to develop a bioresorbable scaffold material for applications in advanced wound healing, i.e., diabetic ulcers and pressure sores. The specific goal is to develop a highly porous biomaterial that is bifunctional, i.e., used as a dressing material for wounds treated with vacuum therapy (Negative Pressure Wound Therapy-NPWT), and also serve as a scaffold for tissue regeneration. Research shows that patients treated with NPWT have to undergo several painful dressing changes due to the tissue ingrowth that occurs into current dressings. Further, this repeated injury during dressing changes further delays healing. The project will address this important unmet need by developing a resorbable dressing-scaffold material that will allow ingrowth during NPWT, and then degrade at a desired rate to allow normal tissue to be regenerated and organized within the wounds. The technology addresses major clinical unmet needs in advanced wound healing and will produce significant reductions in treatment costs while improving the quality of life for patients who suffer from these debilitating wounds.<br/><br/>The broader impacts of this research are in a variety of applications in tissue regeneration and repair for general, cardiothoracic, and plastic surgery; trauma, sportsmedicine, and fracture healing. This novel scaffold technology will be developed within the framework of large scale foam manufacturing methods using industrial foaming and thermal reticulation techniques. This will also reduce the cost of the biomaterial and substantially impact healthcare spending across a broad range of clinical application areas in the US.

  • Program Officer
    Gregory T. Baxter
  • Min Amd Letter Date
    10/30/2009 - 14 years ago
  • Max Amd Letter Date
    7/6/2010 - 14 years ago
  • ARRA Amount

Institutions

  • Name
    Biomerix Corporation
  • City
    New York
  • State
    NY
  • Country
    United States
  • Address
    142 W 57TH ST FL 4A
  • Postal Code
    100193300
  • Phone Number
    5109331228

Investigators

  • First Name
    Balakrishna
  • Last Name
    Haridas
  • Email Address
    bharidas@biomerix.com
  • Start Date
    10/30/2009 12:00:00 AM
  • End Date
    07/06/2010
  • First Name
    Maybelle
  • Last Name
    Jordan
  • Email Address
    mjordan@biomerix.com
  • Start Date
    7/6/2010 12:00:00 AM

FOA Information

  • Name
    Industrial Technology
  • Code
    308000